Aristotle University Of Thessaloniki (AUTH)
Ανάπτυξη και αξιολόγηση ραδιοεπισημασμένων συνθετικών αναλόγων της σωματοστατίνης για την in vivo εντόπιση νεοπλασμάτων
Abstract
dc:descriptionThe overexpression of somatostatin receptor subtype 2 (sst2) in many neoplasms of mainly neuroendocrine origin has resulted in an established method for the in vivo diagnostic imaging of sst2-positive tumors using OctreoScan® ([111Ιn-DTPA0]octreotide). Despite its initial success, OctreoScan®’s broader application is hampered by using 111In. Given that, 99mTc still remains the ideal diagnostic radionuclide of nuclear medicine due to important practical and financial advantages the development of a specific sst2-seeking [99mTc]-radiotracer as an alternative to OctreoScan® is highly attractive. In the present thesis, the synthesis and the biological evaluation of two novel somatostatin peptide analogs, functionalized at the N-terminus with an acyclic tetraamine chelator for effective 99mTc binding: Demotide ([Ν40,Tyr3]octreotide) and Demotate ([Ν40,Tyr3]octreotate) differing only at the C-terminus (Thr(ol)8 versus Thr8-OH, respectively), is described. Synthesis of Demotide was performed in solution whereas Demotate was synthesized on the solid support. Identification of new analogs comprised ESI-MS and RP-HPLC. Their binding affinity for sst2 was determined by competition binding experiments in sst2-positive rat brain cortex or AR4-2J and CA20948 cell membranes. Their hsst1-5 binding profile was determined by in vitro receptor autoradiography. Labeling with 99mTc led to [99mTc]Demotide and [99mTc]Demotate. The radiopeptide affinity for the sst2 was determined by saturation binding assays in AR4-2J membranes and their internalization was tested in AR4-2J cells. Biodistribution was studied in healthy (Swiss albino mice and Wistar rats) and pathological animal models (AR4-2J tumor-bearing Swiss nu/nu mice and CA20948 tumor-bearing Lewis rats). In conclusion, [99mTc]Demotide and [99mTc]Demotate satisfied important criteria and combined a variety of favorable properties for successful application in the targeted diagnostic imaging of sst2-positive tumors in man, such as favorable pharmacokinetics, metabolic stability as well as rapid and high in vivo sst2-targeting. These characteristics provide the prospect to implement a logistically convenient one-day clinical protocol (99mTc: t½= 6.02 h) without compromising image quality. Such a protocol will facilitate the patient management in clinical practice in comparison to OctreoScan® (111In: t½= 67.2 h). The latter is more suitable for a two-day examination protocol according to the manufacturer’s suggestion. Further studies are expected to confirm their potential diagnostic value in the clinic.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2008
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Nikolopoulou, Anastasia
- Νικολοπούλου, Αναστασία
Subjects
dc:subject × 18- Σωματοστατίνη
- Μοριακή στόχευση
- Υποκαταστάτες, Τετρααμινικός
- Όγκοι, Διαγνωστική Απεικόνιση
- Πεπτιδικά ανάλογα
- Όγκοι, Νευροενδοκρινείς
- 99m Tc
- Somatostatin
- Molecular targeting
- Chelator, Tetraamine
- Tumor, Diagnostic Imaging
- Peptide analogues
- Tumors, Neuroendocrine
- Receptors, Somatostatin subtype 2 (sst2)
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/15902